Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 5/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24549349 | 1.00 | GNAI3 (0.38) | GNAI3GNAO1GNAI1KCNH2CCR2 | |
| SCHEMBL21214485 | 0.88 | GNAO1 (0.38) | GNAI3GNAO1GNAI1KCNH2CCR2 | |
| SCHEMBL24429492 | 0.88 | GNAO1 (0.38) | GNAI3GNAO1GNAI1KCNH2CCR2 | |
| SCHEMBL19226599 | 0.87 | KCNH2 (0.40) | KCNH2CCR2KDM1AMAOB | |
| SCHEMBL19226618 | 0.87 | KCNH2 (0.40) | KCNH2CCR2KDM1AMAOB | |
| SCHEMBL19226652 | 0.85 | GNAO1 (0.36) | GNAI3GNAO1GNAI1KCNH2CCR2 | |
| SCHEMBL22648554 | 0.85 | GNAO1 (0.36) | GNAI3GNAO1GNAI1KCNH2CCR2 | |
| SCHEMBL21214461 | 0.83 | KCNH2 (0.48) | GNAI3GNAO1GNAI1KCNH2EPHX1 | |
| SCHEMBL24549450 | 0.83 | KCNH2 (0.35) | GNAI3GNAO1GNAI1KCNH2CCR2 | |
| SCHEMBL22648450 | 0.83 | KCNH2 (0.35) | GNAI3GNAO1GNAI1KCNH2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN2, ERN1 | GNAI3 1504/4885GNAO1 3151/4885GNAI1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.